TYK2 What has been happening since?10 Sep 2019 21:57
Cambridge, UK-June 26, 2014—Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Melissa Works, Ph.D., of SRI International will present the latest data from the Sareum/SRI collaboration that is developing TYK2 kinase inhibitors as treatments for inflammatory diseases at the Federation of Clinical Immunology Societies (FOCiS) conference.